#153716

NUCOLL43 Cell Line

Please Enter Your Email ID
Email ID

Cat. #153716

NUCOLL43 Cell Line

Cat. #: 153716

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Ovary

Disease: Cancer

Model: Cancer Model

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Nicola Curtin

Institute: Northern Institute For Cancer Research, Newcastle University

Tool Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: NUCOLL43 Cell Line
  • Alternate name: O-CCC, ovarian clear cell carcinoma, HGSC, high grade ovarian cancer, TP53, CA125, LOH, loss of heterozygosity
  • Cancer: Gynaecologic cancer
  • Cancers detailed: Ovarian clear cell carcinoma
  • Research fields: Cancer;Cell biology;Genetics
  • Tool sub type: Primary
  • Parental cell: Clear cell adenocarcinoma of gynecological origin
  • Organism: Human
  • Gender: Female
  • Tissue: Ovary
  • Disease: Cancer
  • Growth properties: Doubling time approximately 45 hours
  • Model: Cancer Model
  • Conditional: No
  • Description: Ovarian cancer is a significant cause of death in women worldwide with the majority of ovarian cancers forming in women under the age of 65. Due to late stage diagnosis and a lack of reliable screening tests, survival rates after 5 years are below 50% in developing counties. Ovarian cancer can spread to tissues in close proximity to the ovaries, including the lining of the abdomen, lungs, lymph nodes and liver. Ovarian cancer has a number of histological subtypes and ovarian clear cell carcinomas generally respond poorly to chemotherapy. NUCOLL43 was established from ascitic fluid from a female 57 year old white British patient without artifical immortalisation. Cells display a complete loss of TP53 expression and function despite having no loss of chromosome 17p and show highly similar pan-genomic similarity to the original patient tumor. Like the original tumor, the cells also expressed epithelial and mesenchymal characteristics. NUCOLL43 cells poses a very high degree of loss of heterozygosity which affected 85% of the genome.NUCOLL43 cells are resistant to cisplatin and rucaparib, but sensitive to paclitaxel, camptothecin and NVP-BEZ 235.
  • Biosafety level: 1

Applications

  • Application notes: NUCOLL43 was established from ascitic fluid from a female 57 year old white British patient without artifical immortalisation. Cells display a complete loss of TP53 expression and function despite having no loss of chromosome 17p and show highly similar pan-genomic similarity to the original patient tumor. Like the original tumor, the cells also expressed epithelial and mesenchymal characteristics. NUCOLL43 cells poses a very high degree of loss of heterozygosity which affected 85% of the...

Handling

  • Format: Frozen
  • Growth medium: RPMI-1640 media supplemented with 20% FBS and cultured at 37?‚°C in 5% CO2.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • Franklin et al. 2018. Cancer Med. :. PMID: 30109783.
  • Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.